QIAGEN N.V. (QGEN): Financial results for Q2 2026
QIAGEN N.V. (QGEN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Media Release QIAGEN exceeds Q2 2026 outlook as pillars deliver solid sales growth; reaffirms full-year outlook • Q2 2026 results: ◦ Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outl
How this was made
The 30-second read
Why it matters
The earnings release provides fresh guidance and dividend increase, offering a clear trading catalyst.
Market read
First‑report earnings beat with dividend hike gives traders a fresh decision point.
What to watch
Currency headwinds and upcoming product launches could affect future quarters.
QIAGEN exceeds Q2 2026 outlook as pillars deliver solid sales growth; reaffirms full-year outlook
Q2 net sales of $535 million were unchanged on a reported basis and at CER but exceeded outlook for an about 2% CER decline, while adjusted diluted EPS of $0.62 exceeded outlook for at least $0.60 CER. Growth pillars delivered approximately 5% CER growth, offsetting continued U.S. Life Sciences instrument-spending pressure and portfolio declines.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, Q2 2026GAAP | $535 million | – | 0 % |
| Net sales, Q2 2026 CERother | $531 million | – | 0 % |
| Gross profit, Q2 2026GAAP | $340.4 million | – | – |
| Adjusted gross margin, Q2 2026non-GAAP | 66.2% of sales | – | – |
| Operating income, Q2 2026GAAP | $132 million | – | +9 % |
| Adjusted operating income, Q2 2026non-GAAP | $157 million | – | -2 % |
| Adjusted operating income margin, Q2 2026non-GAAP | 29.4% | – | – |
| Total operating expenses, Q2 2026GAAP | $208.0 million | – | – |
| Sales and marketing expenses, Q2 2026GAAP | 21.8% of sales | – | – |
| Research and development expenses, Q2 2026GAAP | 9.4% of sales | – | – |
| General and administrative expenses, Q2 2026GAAP | 5.6% of sales | – | – |
| Net income, Q2 2026GAAP | $103 million | – | +7 % |
| Adjusted net income, Q2 2026non-GAAP | $129 million | – | -2 % |
| Diluted EPS, Q2 2026GAAP | $0.50 | – | +14 % |
| Adjusted diluted EPS, Q2 2026non-GAAP | $0.62 | – | +3 % |
| Adjusted diluted EPS, Q2 2026 CERother | $0.62 | – | +3 % |
| Adjusted tax rate, Q2 2026non-GAAP | 18% | – | – |
| Diluted share count, Q2 2026GAAP | 207.8 million | – | – |
| Net sales, H1 2026GAAP | $1,027 million | – | +1 % |
| Net sales, H1 2026 CERother | $1,008 million | – | -1 % |
| Gross profit, H1 2026GAAP | $650.0 million | – | – |
| Operating income, H1 2026GAAP | $217 million | – | -9 % |
| Adjusted operating income, H1 2026non-GAAP | $292 million | – | -4 % |
| Net income, H1 2026GAAP | $171 million | – | -8 % |
| Adjusted net income, H1 2026non-GAAP | $242 million | – | -4 % |
| Diluted EPS, H1 2026GAAP | $0.82 | – | -4 % |
| Adjusted diluted EPS, H1 2026non-GAAP | $1.16 | – | +1 % |
| Adjusted diluted EPS, H1 2026 CERother | $1.15 | – | 0 % |
| Net cash provided by operating activities, Q2 2026GAAP | $201 million | – | +24 % |
| Free cash flow, Q2 2026non-GAAP | $158 million | – | +30 % |
| Net cash provided by operating activities, H1 2026GAAP | $301 million | – | 0 % |
| Free cash flow, H1 2026non-GAAP | $212 million | – | -3 % |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Sample technologiesConsumables sales grew at a high single-digit CER rate and instrument sales increased at a mid single-digit CER rate. Parse contributed to growth, while automated consumables delivered high teens CER growth. | $182 million | – | +9 % CER |
| Diagnostic solutionsQuantiFERON sales rose 1% CER, but consumables and instruments declined and QIAstat-Dx faced a demanding respiratory-testing comparison. | $204 million | – | -2 % CER |
| QuantiFERONSolid demand across many testing groups more than offset continued weakness in U.S. immigration testing. | $131 million | – | +1 % CER |
| QIAstat-DxSales declined against a demanding prior-year comparison for respiratory testing, partly offset by growth in Gastrointestinal and Meningitis / Encephalitis panels. | $32 million | – | -7 % CER |
| NeuMoDxThe discontinuation was completed in June 2025. | — | – | -100 % CER |
| Other diagnostic solutionsIncluded double-digit CER growth in Precision Medicine consumables for companion diagnostics tied to pharmaceutical co-development agreements. | $40 million | – | 0 % CER |
| PCR / Nucleic acid amplificationQIAcuity grew at a double-digit CER rate, but weaker OEM demand and lower sales of other PCR consumables and instruments drove the product-group decline. | $74 million | – | -8 % CER |
| Genomics / Next-generation sequencing (NGS)QIAGEN Digital Insights delivered good single-digit CER growth and universal NGS panels rose more than 20% CER, partly offset by lower sales of other genomics products. | $61 million | – | +2 % CER |
| OtherNo driver was provided. | $15 million | – | -34 % CER |
FY 2026 and Q3 2026 outlook
- RevenueFY 2026: net sales growth of about 1-2% CER; Q3 2026: net sales are expected to rise approximately 1-2% CER from $533 million in Q3 2025.
- NoteFY 2026: adjusted diluted EPS of at least $2.43 CER.
- NoteQ3 2026: adjusted diluted EPS is expected to be at least $0.62 CER compared to $0.61 in Q3 2025.
- NoteFY 2026: currency movements against the U.S. dollar are expected to have a positive impact on net sales of about one percentage point and a neutral impact on adjusted EPS results.
- NoteQ3 2026: currency movements against the U.S. dollar are expected to have a negative impact on net sales of about one percentage point and a neutral impact on adjusted EPS results.
- NoteQuantiFERON sales are expected to continue progressing toward the 2026 goal of approximately $500 million.
- NoteContributions from the Parse acquisition are expected to track above the 2026 target for about $40 million of sales.
Capital returns
- The $500 million synthetic share repurchase in January 2026.
- The dividend payment of about $72 million, a 40% increase per share from 2025, was made in July 2026.
- Capital repayment was $(496,749) in H1 2026 compared with $(280,086) in H1 2025.
What drove it
- Growth pillars together delivered approximately 5% CER growth, led by Sample technologies, QIAcuity and QIAGEN Digital Insights.
- Sample technologies grew 9% CER, including a 3% CER increase excluding contributions from the Parse acquisition completed in December 2025.
- QIAcuity sales grew at a double-digit CER rate, driven by consumables growth well above that level and supported by ongoing instrument placements.
- QIAGEN Digital Insights delivered good single-digit CER growth, led by the clinical business, which represents about half of QDI sales.
- Efficiency gains and disciplined cost management reduced sales and marketing expenses to 21.8% of sales from 22.1% in Q2 2025.
Concerns
- Instrument sales declined at a low teens CER rate amid a continued cautious capital-spending environment among U.S. Life Sciences customers.
- QuantiFERON sales rose 1% CER as continued weakness in U.S. immigration testing persisted.
- PCR / Nucleic acid amplification sales declined 8% CER, primarily reflecting weaker OEM demand from third-party companies and lower sales of other PCR consumables and instruments.
- QIAstat-Dx sales declined 7% CER against a demanding prior-year comparison for respiratory testing.
- Adjusted gross margin declined to 66.2% from 66.7% in Q2 2025 due to changes in product mix.
- H1 2026 results included about $20 million in cash payments for efficiency and restructuring programs and increased inventory levels in response to geopolitical conditions and new product launches.
What to watch
- Q3 2026 net sales are expected to rise approximately 1-2% CER from $533 million in Q3 2025.
- Q3 2026 adjusted diluted EPS is expected to be at least $0.62 CER compared to $0.61 in Q3 2025.
- QIAGEN expects stronger sales growth in the second half of 2026, supported by new product launches and the absence of prior-year sales from discontinued NeuMoDx and Dialunox portfolios.
- QIAmini remains on track for commercialization in the second half of 2026.
- Parse remains on track to exceed the 2026 sales target of about $40 million.
- QuantiFERON is progressing toward the 2026 goal of approximately $500 million.
Balance sheet and cash flow
- As of June 30, 2026, cash, cash equivalents and short-term investments were $0.8 billion compared with $1.1 billion at year-end 2025.
- Cash and cash equivalents were $768,500 thousand as of June 30, 2026, compared with $839,005 thousand as of December 31, 2025.
- Short-term investments were $25,000 thousand as of June 30, 2026, compared with $259,913 thousand as of December 31, 2025.
- Current portion of long-term debt was $16,517 thousand as of June 30, 2026.
- Long-term debt, net of current portion, was $1,627,105 thousand as of June 30, 2026, compared with $1,654,428 thousand as of December 31, 2025.
- The leverage ratio, net debt to adjusted EBITDA, increased to 1.1x at the end of Q2 2026 from 0.7x at the end of 2025.
- Purchases of property, plant and equipment were $(90) million in H1 2026 compared with $(84) million in H1 2025.
- Net cash provided by investing activities was $141 million in H1 2026 compared with $78 million in H1 2025.
- Net cash used in financing activities was $(512) million in H1 2026 compared with $(315) million in H1 2025.
Analysis
QIAGEN reported Q2 2026 net sales of $535 million, unchanged from Q2 2025 on both a reported and CER basis. This exceeded the company outlook for an about 2% CER decline. Adjusted diluted EPS of $0.62, also $0.62 at CER, exceeded outlook for at least $0.60 CER, while GAAP diluted EPS rose to $0.50 from $0.44. The company reaffirmed full-year outlook for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER.
Portfolio mix was the principal source of resilience. Growth pillars delivered approximately 5% CER growth, led by Sample technologies at 9% CER. The group benefited from high single-digit CER consumables growth, mid single-digit CER instrument growth and Parse contributions. QIAcuity posted double-digit CER sales growth and QIAGEN Digital Insights delivered good single-digit CER growth. These advances were counterbalanced by a low teens CER decline in total instrument sales, an 8% CER decline in PCR / Nucleic acid amplification, and a 2% CER decline in Diagnostic solutions.
Profitability remained high but showed mix and investment effects. Adjusted operating income was $157 million, down 2%, and the adjusted operating income margin was 29.4%, compared with 29.9% in Q2 2025. Adjusted gross margin was 66.2%, compared with 66.7%, due to product mix. Sales and marketing expenses improved to 21.8% of sales from 22.1%, while R&D rose to 9.4% from 8.9% as QIAGEN supported investments in growth pillars and Parse.
Cash generation was strong in the quarter, with Q2 operating cash flow of $201 million and free cash flow of $158 million. H1 operating cash flow was unchanged at $301 million, while H1 free cash flow was $212 million compared with $217 million, reflecting higher investments in strategic IT initiatives and Parse. Capital deployment included a $500 million synthetic share repurchase in January 2026 and a dividend payment of about $72 million in July 2026. Cash, cash equivalents and short-term investments were $0.8 billion as of June 30, 2026, and leverage was 1.1x.
Management expects stronger sales growth in the second half of 2026, citing product launches and the absence of prior-year sales from discontinued NeuMoDx and Dialunox portfolios. Q3 guidance calls for approximately 1-2% CER net-sales growth from $533 million in Q3 2025 and adjusted diluted EPS of at least $0.62 CER. Execution in U.S. Life Sciences instrument demand, QuantiFERON amid lower U.S. immigration testing demand, and commercialization of QIAmini will be important reported indicators.
Management, verbatim
QIAGEN delivered results above our outlook for the second quarter of 2026 while maintaining a high level of profitability in a challenging operating environment.
Thierry Bernard, Chief Executive Officer of QIAGEN
Our adjusted operating income margin remained strong and improved from Q1 2026 while supporting targeted investments following the Parse acquisition and absorbing adverse currency headwinds.
Roland Sackers, Chief Financial Officer of QIAGEN
Not in the filing
stated, not guessed- Prior-quarter comparisons for revenue, segment sales, profitability metrics, EPS and cash flow were not reported.
- GAAP gross margin was not reported.
- FY 2026 and Q3 2026 gross-margin, operating-expense and tax-rate guidance were not reported.
- Total debt was not reported as a single line item.
- No previous-release outlook was provided, so no comparison with prior guidance is available.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
QIAgen is a Dutch‑based molecular diagnostics company listed on NYSE (QGEN).
Ticker impact
QIAgen reported Q2 2026 net sales of $535M and adjusted EPS of $0.62, beating outlook and reaffirming full-year guidance.
Potential modest price rise in after‑hours trading, with upside if guidance holds.
The company delivered better‑than‑expected earnings and raised its dividend, indicating strong cash flow and profitability.
Market effects
Positive earnings may lift other life‑science diagnostics peers.
European and US biotech markets could see modest gains.
Limited to diagnostics sector; no broad market shift expected.
Counterpoint
If instrument sales slowdown persists, the beat may be temporary.
Key entities
- ExecutiveThierry Bernard
CEO of QIAgen, quoted on earnings performance.
- ExecutiveRoland Sackers
CFO of QIAgen, discussed dividend increase and Parse acquisition.
